PLEASE NOTE: Change to OUHSC new NIH Other Support pages requirements. OUHSC will not start implementing this policy internally until October 01, 2021 (previously July 1, 2021). Please keep in mind, that other institutions may have already implemented this policy and you may be required to use the new format for them before the OUHSC October 01, 2021 date.
Effective immediately, all Human Subject Research (HSR) activities including clinical trials are allowed to resume provided all OUHSC COVID-19 safety protocols can be met. It is expected that all personnel will adhere to the requirements in the OUHSC COVID-19 Response Plan. If your current HSR protocol was temporarily halted due to the COVID-19 restrictions, the HRPP Office will update the study status of those protocols without any action required from you.
Also, in accordance with campus policy, our research laboratories* remain closed to K-12 students for shadowing, volunteer, and educational purposes, but open to visitors, undergraduates, graduates, and post-docs from any institution for those purposes, provided the following are observed by these individuals. The manager of the area where these individuals will be is responsible for compliance:
- individuals will be required to show proof of a negative COVID test (within past 48 hours) or documentation of COVID vaccination, if required based on screening results
- all individuals will complete the HSC online COVID-19 training module in OnPoint, using their HSC credentials
- all individuals (including students, faculty, staff, and volunteers) will comply with OU’s COVID-19 vaccine policy:
- those with patient-facing or research participant-facing responsibilities or who will be in patient care or human research
- all other individuals will be strongly encouraged to be vaccinated against COVID-19
* all individuals will be informed that they must comply with and be given the link to the HSC COVID-19 Response Plan
Rotations in clinical areas on campus and at OUMI are limited to OUHSC students, at least through July 2021.
With these changes, we are retiring the Return to Research Plan and will refer to the OUHSC COVID Response Plan for COVID protocols.
If you identify a deficiency caused by this action, please email firstname.lastname@example.org.
OK-INBRE REQUEST FOR APPLICATIONS FOR RESEARCH PROJECTS
The Oklahoma IDeA Network of Biomedical Research Excellence (OK-INBRE) is requesting applications for research projects from full-time, tenure track faculty (or equivalent) at the University of Oklahoma Health Sciences Center (OUHSC) or the Oklahoma Medical Research Foundation (OMRF). OK-INBRE will fund four Research Project Investigator (RPI) Awards with a start date of November 1, 2021 and an end date of April 30, 2024. Funding for awards is anticipated to be $100,000 in direct costs per year. Applications must align with one of the OK-INBRE research themes of 1) Cancer, 2) Developmental Biology, or 3) Infectious Diseases. The application deadline is 5pm on August 13, 2021. Please see the attached funding opportunity announcement for details. Information can also be found on the OK-INBRE website at Funding Opportunities for OUHSC and OMRF. Questions regarding this OK-INBRE opportunity can be sent to Dawn Hammon (email@example.com) or Darrin Akins (firstname.lastname@example.org).
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email email@example.com or firstname.lastname@example.org).
- Reckitt is seeking to engage with academic partners to 1) develop approaches to enhance oral drug delivery into the pharyngeal, esophageal, or colon; 2) enhance the safety of OTC medications, or 3) develop natural/non-medicated solutions for upper and lower GI conditions, sore throat, cough, cold, flu, and pain. Submission entails a 1-pg non-confidential summary of technology (deadline 5/27/2021)
- Pfizer’s Centers for Therapeutic Innovation (https://www.pfizercti.com) is seeking collaborative proposals for developing novel therapeutic targets with application in 1) oncology: tumor targeted, immuno-oncology, cancer vaccines; 2) internal medicine: obesity/cachexia, heart failure, diabetic/CKD, NASH/T2D; 3) inflammation and immunology: rheumatology, gastroenterology, medical derm; or 4) rare disease: cardiology, neuro-musc., metabolic, hematology. Preference is for novel biological targets supported by in vivo and in vitro models, enabling genetics and mechanistic insights, translational biochemical or cellular assay and biomarkers. Out of scope: drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies.
- Proposal template available upon request (submission deadline 6/18/21).
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( email@example.com ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
NHLBI Announces Availability of Frequently Asked Questions (FAQs) for RFA-HL-20-006 Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Independent Clinical Trial Not Allowed) (NOT-HL-21-013)
Availability of Frequently Asked Questions (FAQs) for RFA-HL-22-007 and RFA-HL-22-008: Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Program (NOT-HL-21-014)
Notice to Extend the Response Date for NOT-LM-21-005, "Request for Information (RFI): Use of Common Data Elements (CDEs) in NIH-funded Research" (NOT-LM-21-008)
Notice of Correction to Award Budget for PA-21-235, "NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)" (NOT-MH-21-290)
Request for Information (RFI): Seeking Stakeholder Input on Enhancing Diversity and Inclusion in the Cancer Research Workforce (NOT-CA-21-067)
Request for Information (RFI): Facilitating the Early Diagnosis and Equitable Delivery of Gene-Targeted Therapies to Individuals with Rare Diseases (NOT-TR-21-027)
Notice of Change to Eligibility Information for RFA-AA-20-013 "Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional) (NOT-AA-21-030)
Notice of NIAAA's participation in NOT-NS-21-049, "Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities" (NOT-AA-21-031)
Notice of NIDCD Withdrawal from Participation in PA-20-184, "Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) (NOT-DC-21-002)
Notice of Correction to the Application and Submission Instructions for the Pilot and Feasibility Program for RFA-DK-21-015, Nutrition Obesity Research Centers (P30 Clinical Trial Optional) (NOT-DK-21-020)
Notice of Termination of NIEHS Participation on NOT-EB-21-012, Notice of Extension of the Expiration Date of PAR-19-159,"Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)" (NOT-ES-21-007)
Notice of Correction to NOT-OD-21-103, "Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (Emergency Supplement – Clinical Trial Optional) (NOT-OD-21-125)
Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed) (NOT-CA-21-079)
Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (DRCC) (U24 Clinical Trial Not Allowed) (NOT-CA-21-080)
Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Medtech: Small Business Translator (U44) (NOT-DA-22-050)
Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint MedTech: Prototyper Prototype Developer (U18 Clinical Trial Not Allowed) (NOT-EB-21-018)
Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint MedTech: Incubator Hubs (U54 Clinical Trial Not Allowed) (NOT-EB-21-019)
Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint MedTech: Translator (UG3/UH3 Clinical Trial Optional) (NOT-NS-21-057)
Notice of Special Interest (NOSI): Availability of Urgent Award for Competitive Revisions to IDeA-CTR Awards to Address the Continued Need for Documenting COVID-19-Related Patient Outcomes (NOT-GM-21-050)
Notice of Special Interest (NOSI): Administrative Supplements to Enhance Data Science Capacity at NIMHD-Funded Research Centers in Minority Institutions (RCMI) (NOT-MD-21-021)
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) (PA-21-180) - Deadline June 16, 2021 and October 16, 2021
Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required) (PA-21-205) – Deadline September 7, 2021 and January 7, 2022
Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
(PA-21-219) – Deadline June 16, 2021 and October 16, 2021
NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed) (PA-21-235)
Deadline June 16, 2021 and October 16, 2021
Summer Research Education Experience Program (R25 Clinical Trial Not Allowed) (PAR-21-168)
Deadline March 17, 2022 and March 17, 2023
Emerging Science and Technology in Transplantation (U01 Clinical Trial Not Allowed) (RFA-AI-21-016)
Deadline September 03, 2021
SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
(RFA-ES-21-005) - Deadline July 30, 2021
T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed)
(RFA-HL-22-001) - Deadline September 13, 2021 an February 28, 2022
OTHER FEDERAL DEADLINES
Department of Defense (DOD) – Pancreatic Cancer Research Program (PCARP) – Idea Development Award Required PreApplication due July 01, 2021
DOD – PCARP – Translational Research Partnership Award – Required PreApplication due July 01, 2021
DOD – Vision Research Program (VRP) – Clinical Trial Award – PreApplication due July 21, 2021
DOD – VRP – Focused Translational Team Science Award – PreApplication due July 21, 2021
DOD – VRP – Investigator Initiated Research Award – PreApplication due July 21, 2021
DOD – VRP – Translational Research Award – PreApplication due July 21, 2021
DOD – Rare Cancers Research Program (RCRP) – Concept Award – PreApplication due July 13, 2021
DOD – RCRP – Idea Development Award – PreApplication due July 13, 2021
DOD – RCRP – Resource and Community Development Award – PreApplication due July 13, 2021